Overactive Bladder Clinical Trial
Official title:
A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy of Dried Cranberry at 500 mg Daily in Women With Dry Overactive Bladder for 6 Months
A randomized, double-blind, placebo controlled study to evaluate the efficacy of dried cranberry at 500 mg daily in women with overactive bladder for 6-months.
This is a 6 month, randomized, prospective, single-center trial that will be conducted in an
outpatient setting at a tertiary care facility. This will be a double-blind, randomized,
placebo-controlled parallel study of dried cranberry for OAB symptoms in women. Eligible
subjects will be female outpatients aged ≥18 years who have been diagnosed with OAB. All
patients will be provided written informed consent before entering the study. The study
protocol and all amendments will be approved by the appropriate Institutional Review Board.
Patients will be recruited for the study from the office of Dr. Bilal Chughtai, from within
Weill Cornell Medical College, including referral by WCMC-affiliated primary care and other
physicians not involved with the study, as well as recruited from advertisement (Craigslist,
newspapers, posters, etc.). Recruitment will also take place within New York Presbyterian
Hospital.
Subjects will have a complete history and physical examination in the office; the
participants will complete the validated questionnaires and informed consent, as well as
urinalysis. Eligible participants will be enrolled in the study and randomized to receive
either a dried cranberry or placebo. The primary endpoint is the mean change in number of
voids per day as measured using a three-day voiding diaries from baseline to
end-of-treatment. Patients will complete voiding diaries for 3 consecutive days prior to each
clinic visit. Secondary endpoints will include a comparison of the patient's baseline OAB
symptom bother and quality of life, and sexual function as measured by 4 validated
questionnaires: the OABQ-SF, PPBC, SQOL-F, and PFDI-20.
The subjects will be given a device to measure their urinary volume throughout the study.
The study duration will be 6 months. Follow-up visits will be conducted at 12 and 24 weeks.
Adverse reactions and complications will be obtained and recorded by Clavien-Dindo Grading
System.
The investigator seeks to determine if dried cranberry powder changes the microbiome of women
with Overactive Bladder symptoms versus placebo. At visit two (baseline) and visit four (end
of study visit) stool and urine samples will be collected from up to 40 study participants
out of the 76 participants enrolled in the study. The stool and urine samples will be
collected and the microbiome of each specimen will be analyzed by Genomics Core or
Epigenomics Core at Weill Cornell Medical College.
Participants in the study will provide urine samples. The urine sample will be collected in
sterile containers. Participants in the study will provide one urine sample during visit 2
(Baseline visit) and another sample during visit 4 (end of study). These samples will be
subsequently analyzed for the presence/ absence of microbiota. This includes DNA extraction,
library preparation, shotgun next-generation sequencing, and follow-up metagenomics and
microbiome analysis using bioinformatics alignment tools, in order to identify microbial
species and strains. Participants in the study will provide one stool sample during visit 2
of the study and another during visit 4 of the study. Stool samples will be self-collected
using a clean catching receptacle (e.g. plastic inverted hat) and plastic scoop to transfer
feces into 6 sterile tubes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Completed |
NCT02667470 -
Reproducibility Study of OABSS and Its Response to Treatment
|
Phase 4 |